Labiotech.eu

News and Trends 15 Jul 2015

GSK becomes the first Pharma to collaborate with the Francis Crick Institute

The future Francis Crick Institute has established its first industrial collaboration, even before opening its doors. And the lucky nominee couldn’t have been any other than GlaxoSmithKline, the UK’s largest pharmaceutical company. The partners are seeking to better understand human diseases, hoping that the research will lead to innovative drugs against a broad range of disorders. The […]

July 15, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 14 Jul 2015

Newron’s ressurection story continues with a FDA Orphan Drug designation

New success for Newron Pharmaceuticals. The FDA approved Orphan Drug designation to its new chemical entity Sarizotan, designed to treat patients suffering from Rett syndrome. This decision fits the one from the European Medicine Agency, whose Committee for Orphan Medical Products positively reviewed the drug last month. The Italian pharma company Newron with a market […]

July 14, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 14 Jul 2015

Probiodrug bets on basic research with Harvard’s collaboration

Probiodrug will provide research funding to the laboratory of Cynthia Ann Lemere in the Center for Neurologic Diseases at Brigham and Women’s Hospital, a teaching hospital affiliated with Harvard Medical School. Dr. Lemere is pioneering immunotherapy approaches to eliminate pyroglutamated (pGlu) Abeta, a highly toxic peptide that has been linked to the progression of Alzheimer’s disease. […]

July 14, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 13 Jul 2015

Researchers found the missing key factor to unleash the potential of iPS Cells

When the Nobel Prize-winning Dr. Shinya Yamanaka succeeded to generate induced pluripotent cells (iPS cells) from specialized adult cells, the field of stem cells was completely revolutionized. Since Yamanaka’s paper on adult mouse fibroblasts back in 2006, scientists have been able to perform cellular reprogramming, but the process still isn’t mastered yet. One of the […]

July 13, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 13 Jul 2015

ReNeuron backed by First-Class Investor Woodford to advance Stem Cell Therapy

The stem cell therapy developer ReNeuron raised €96M to conduct further clinical trials of its pipeline, and more specifically to pursue potential stroke, eye disease, and cancer treatments. The financial placement is supported by the already major shareholder Woodford Investment Management, allowing the latter to possess more than one-third of the company shares. ReNeuron, a […]

July 13, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 13 Jul 2015

After being rejected twice, Horizon pushes Depomed to accept its €2.7Bn offer

Horizon Pharma is getting anxious and has offered the substantial amount of €2.7Bn to buy its American competitor Depomed. The Irish drug-maker plans to add the US-based firm to its shopping list just after enrolling Hyperion Therapeutics, the company that was purchased only one month ago. Dublin-based Horizon has been pursuing Depomed lately, but the American company is playing […]

July 13, 2015 - 1 minutemin - By Lourdes Riquelme

bactman synthetic biology videogame paris supbiotech

News and Trends 12 Jul 2015

Cool iGEM Project: Creating the first Synthetic Biology-based Video Game

It’s iGEM- Time, the world’s biggest synthetic biology competition! Since 2004, students are competing to create, explore and share their innovative ideas in the hot field of synthetic biology. All the teams then go to Boston (not at the MIT anymore since it’s stopped organizing the competition) to be judged and win a prize. Each year, […]

July 12, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 10 Jul 2015

First-in-human successful Phase I for an Alzheimer’s vaccine

AXON Neuroscience has completed a pioneer Phase I that offers new hope for millions of patients with Alzheimer’s disease. This makes AXON the first company to successfully complete this clinical trial for a vaccine that targets diseased tau proteins, which cause neural degeneration. Alzheimer’s disease is characterized by the presence of prejudicial forms of protein […]

July 10, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 10 Jul 2015

Sanofi to solve Growing Resistance against Malarial Treatments

Sanofi extended its collaboration with Medicines for Malaria Venture (MMV) to jointly develop a new combination therapy against malaria, the deadliest parasitic disease worldwide. The difficult access and the fear of a growing resistance to the existing treatments highlight the importance of this partnership. Atemisinin-based combination therapies (ACT) are at this moment the most efficient […]

July 10, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 10 Jul 2015

Greenovation: Using Moss as a Drug Production Factory

Factor H, a key component of the immune system that is missing in patients suffering from atypical hemolytic uremic syndrome (aHUS) was effectively produced in the moss Physcomitrella patens. In collaboration with the University of Freiburg, Greenovation now aims to humanize the protein to suit it for clinical use. The complement system is part of […]

July 10, 2015 - 2 minutesmins - By Philip Hemme

eye Bayer Healthcare Johns Hopkins University

News and Trends 9 Jul 2015

Vision specialist Gensight eyes a €90M IPO on NASDAQ

French Gensight intends to raise one of the biggest European IPOs on the American stock market. The gene-therapy specialist will pursue €90.6M to advance with two early-stage candidates for orphan eyes diseases. Gensight will travel across the Ocean to look for the same success its compatriots had on the American stock market. The company will […]

July 9, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 9 Jul 2015

Oasmia anticipates an Oncology market growth and seeks €23M on NASDAQ

Human and veterinary oncologist Oasmia files for a €23M IPO on the American NASDAQ. The Swedish company, anticipating an increase in the oncology field, seeks to increase its visibility and to establish itself in the US. The papers have been sent, Oasmia Pharmaceutical will go to NASDAQ under the symbol OAX. The Swedish company was […]

July 9, 2015 - 2 minutesmins - By Lourdes Riquelme

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

GSK becomes the first Pharma to collaborate with the Francis Crick Institute

Newron’s ressurection story continues with a FDA Orphan Drug designation

Probiodrug bets on basic research with Harvard’s collaboration

Researchers found the missing key factor to unleash the potential of iPS Cells

ReNeuron backed by First-Class Investor Woodford to advance Stem Cell Therapy

After being rejected twice, Horizon pushes Depomed to accept its €2.7Bn offer

Cool iGEM Project: Creating the first Synthetic Biology-based Video Game

First-in-human successful Phase I for an Alzheimer’s vaccine

Sanofi to solve Growing Resistance against Malarial Treatments

Greenovation: Using Moss as a Drug Production Factory

Vision specialist Gensight eyes a €90M IPO on NASDAQ

Oasmia anticipates an Oncology market growth and seeks €23M on NASDAQ

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!